Trials / Unknown
UnknownNCT05544812
A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer
The First Affilcated Hosipital ,the Air Force Medical University
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (estimated)
- Sponsor
- Xijing Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to acssess the efficacy and the safety of Sintilimab plus bevacizumab/cetuximab plus XELOX regimen for conversion therapy in patients with advanced colorectal cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sintilimab ，bevcizumab/cetuximab，XELOX | Patients in this group had previously received the following treatment regimens: Oxaliplatin :130 mg/m2, D1, Q3W; Capecitabine :1000mg/m2, bid q2w Sintilimab for injection :200mg, D1, Q3W Bevacizumab :7.5mg/kg, D1, Q3W or cetuximab :500 mg/m, D1, Q2W |
Timeline
- Start date
- 2022-05-01
- Primary completion
- 2022-09-15
- Completion
- 2023-06-30
- First posted
- 2022-09-16
- Last updated
- 2022-09-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05544812. Inclusion in this directory is not an endorsement.